Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SCI-110 · 1 trial · 1 indication
Absolute change from baseline in revised version of YGTSS-R-TTS as a continuous endpoint at week 12 of the respective treatment period. The Global Severity Score has a range of 0- 100. A higher score on the scale suggests a more severe Tic, or a greater impact the Tic has on the person's life.
| Arm | Type | Description |
|---|---|---|
| SCI-110 | EXPERIMENTAL | Cannabinoid-based medication consisting of Dronabinol and PEA |
| Dronabinol | PLACEBO_COMPARATOR | Placebo matched in taste, odour and appearance to SCI-110 |
| Name | Type | Description |
|---|---|---|
| SCI-110 | DRUG | SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day. |
| Placebo | OTHER | Pill that matches in taste, odour and appearance to SCI-110 active pills |
Inclusion Criteria: 1. Tourette syndrome according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) 2. Male and female subjects with an age between ≥18 and ≤65 years 3. Total tic score (TTS) of the revised Yale Global Tic Severity Scale (YGTSS-R) \>14 4. Clinical Glo...
SCI-110 is an investigational small molecule being developed for the treatment of Tourette Syndrome. It is a Phase 2 candidate in the neurology therapeutic area, and it is not yet approved for any indication. The clinical program is sponsored by SciSparc Ltd.
SCI-110 is being developed by SciSparc Ltd., a company that trades under the ticker SPRC. SciSparc is the sponsor of the Phase 2 clinical program evaluating the drug in Tourette Syndrome.
SCI-110 is in Phase 2 clinical development for Tourette Syndrome. One Phase 2 trial has been registered, and it has not yet begun recruiting. The drug remains investigational and has not been approved by the FDA or any other regulatory authority.
SCI-110 is being studied in the Phase 2 trial NCT05126888, titled SCI-110 in the Treatment of Tourette Syndrome. The trial is registered in the United States, Germany, and Israel, and is designed to enroll 164 participants aged 18 years and older.
The Phase 2 trial NCT05126888 is a randomized, double-blind, placebo-controlled study of SCI-110 in adults with Tourette Syndrome. It plans to enroll 164 participants aged 18 years and older across sites in the United States, Germany, and Israel. The trial is not yet recruiting.